Home Cart Sign in  
Chemical Structure| 1891087-61-8 Chemical Structure| 1891087-61-8

Structure of BAY-1816032
CAS No.: 1891087-61-8

Chemical Structure| 1891087-61-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BAY-1816032 is a potent BUB1 (budding uninhibited by benzimidazoles 1) kinase inhibitor with IC50 of 7 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BAY-1816032

CAS No. :1891087-61-8
Formula : C27H24F2N6O4
M.W : 534.51
SMILES Code : FC1=C(C(F)=CC(OCCO)=C1)CN2C3=CC=CC=C3C(C4=NC=C(OC)C(NC5=CC=NC=C5OC)=N4)=N2
MDL No. :MFCD31657337

Safety of BAY-1816032

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF10A cells MCF10A cells 72 h To evaluate the effect of BAY-1816032 on normal mammary epithelial cell proliferation, IC50 was 18 μM. J Exp Clin Cancer Res. 2024 Jun 11;43(1):163.
T-47D cells T-47D cells 72 h To evaluate the effect of BAY-1816032 on Luminal A subtype breast cancer cell proliferation, IC50 was 3.9 μM. J Exp Clin Cancer Res. 2024 Jun 11;43(1):163.
BT-549 cells BT-549 cells 72 h To evaluate the effect of BAY-1816032 on TNBC cell proliferation, IC50 was 1.59 μM. J Exp Clin Cancer Res. 2024 Jun 11;43(1):163.
MDA-MB-468 cells MDA-MB-468 cells 72 h To evaluate the effect of BAY-1816032 on TNBC cell proliferation, IC50 was 2.59 μM. J Exp Clin Cancer Res. 2024 Jun 11;43(1):163.
MDA-MB-231 cells MDA-MB-231 cells 72 h To evaluate the effect of BAY-1816032 on TNBC cell proliferation, IC50 was 2.10 μM. J Exp Clin Cancer Res. 2024 Jun 11;43(1):163.
SUM159 cells SUM159 cells 72 h To evaluate the effect of BAY-1816032 on TNBC cell proliferation, IC50 was 2.90 μM. J Exp Clin Cancer Res. 2024 Jun 11;43(1):163.
HCC1937 cells HCC1937 cells 72 h To evaluate the sensitization effect of BAY1816032 to olaparib in BRCA-mutant TNBC cell line. Results showed that BAY1816032 significantly enhanced the cytotoxicity of olaparib at lower concentrations. Biomolecules. 2024 May 25;14(6):625.
MDA-MB-231 cells MDA-MB-231 cells 72 h To evaluate the cytotoxic effects of BAY1816032 in combination with olaparib, cisplatin, and paclitaxel. Results showed that BAY1816032 significantly enhanced the cytotoxicity of these drugs in TNBC cell lines. Biomolecules. 2024 May 25;14(6):625.
SUM159 cells SUM159 cells 72 h To evaluate the cytotoxic effects of BAY1816032 in combination with olaparib, cisplatin, and paclitaxel. Results showed that BAY1816032 significantly enhanced the cytotoxicity of these drugs in TNBC cell lines. Biomolecules. 2024 May 25;14(6):625.
TPC-1 cells TPC-1 cells 48 h Determination of IC50 value, BAY-1816032 significantly reduced cell viability J Cell Mol Med. 2024 Apr;28(7):e18182.
8505C cells 8505C cells 48 h Determination of IC50 value, BAY-1816032 significantly reduced cell viability J Cell Mol Med. 2024 Apr;28(7):e18182.
bone marrow-derived macrophages (BMMs) bone marrow-derived macrophages (BMMs) BAY1816032 significantly increased osteoclastogenesis in BMMs J Bone Miner Res. 2024 Apr 19;39(3):341-356.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CB17/SCID mice SUM159 mammary fat pad xenograft model Oral 25 mg/kg Twice daily for four weeks To evaluate the effect of BAY-1816032 combined with radiotherapy on SUM159 xenograft tumor growth, results showed that the combination treatment significantly reduced tumor volume and prolonged animal survival. J Exp Clin Cancer Res. 2024 Jun 11;43(1):163.
Nude mice ATC xenograft model Oral 100 mg/kg Once daily for 24 days Evaluation of anti-tumor activity and safety of BAY-1816032, results showed significant reduction in tumor volume and weight J Cell Mol Med. 2024 Apr;28(7):e18182.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.87mL

0.37mL

0.19mL

9.35mL

1.87mL

0.94mL

18.71mL

3.74mL

1.87mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories